T. Rowe Price Associates’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,355
| Closed | -$242K | – | 3067 |
|
|
2024
Q1 | $242K | Buy |
15,355
+1,984
| +15% | +$30.5K | ﹤0.01% | 2531 |
|
|
2023
Q4 | $216K | Buy |
13,371
+1,624
| +14% | +$20.7K | ﹤0.01% | 2514 |
|
|
2023
Q3 | $150K | Buy |
11,747
+1,414
| +14% | +$19.5K | ﹤0.01% | 2576 |
|
|
2023
Q2 | $146K | Sell |
10,333
-589,342
| -98% | -$8.43M | ﹤0.01% | 2614 |
|
|
2023
Q1 | $9.27M | Sell |
599,675
-25,212
| -4% | -$421K | ﹤0.01% | 1072 |
|
|
2022
Q4 | $10.2M | Sell |
624,887
-91,870
| -13% | -$1.49M | ﹤0.01% | 1050 |
|
|
2022
Q3 | $13.3M | Buy |
716,757
+569,958
| +388% | +$8.94M | ﹤0.01% | 1013 |
|
|
2022
Q2 | $1.93M | Buy |
+146,799
| New | +$1.62M | ﹤0.01% | 1629 |
|
|
2022
Q1 | – | Sell |
-311,669
| Closed | -$3.04M | – | 3028 |
|
|
2021
Q4 | $3.04M | Sell |
311,669
-137,430
| -31% | -$2.58M | ﹤0.01% | 1578 |
|
|
2021
Q3 | $15.3M | Sell |
449,099
-70,177
| -14% | -$2.24M | ﹤0.01% | 1358 |
|
|
2021
Q2 | $19M | Sell |
519,276
-648,992
| -56% | -$25.1M | ﹤0.01% | 1310 |
|
|
2021
Q1 | $52.4M | Sell |
1,168,268
-6,624
| -0.6% | -$308K | 0.01% | 987 |
|
|
2020
Q4 | $67.1M | Sell |
1,174,892
-14,595
| -1% | -$865K | 0.01% | 854 |
|
|
2020
Q3 | $61M | Sell |
1,189,487
-349,213
| -23% | -$17.1M | 0.01% | 803 |
|
|
2020
Q2 | $91.9M | Buy |
1,538,700
+62,879
| +4% | +$3.36M | 0.01% | 661 |
|
|
2020
Q1 | $60.8M | Sell |
1,475,821
-215,648
| -13% | -$12M | 0.01% | 716 |
|
|
2019
Q4 | $105M | Buy |
1,691,469
+1,215,965
| +256% | +$57.8M | 0.01% | 651 |
|
|
2019
Q3 | $16.1M | Buy |
+475,504
| New | +$14.1M | ﹤0.01% | 1213 |
|
Other funds holding DCPH
T. Rowe Price Associates's DCPH Position: Q2 2024 in Review
T. Rowe Price Associates sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 15,355 shares — an estimated $242K sold.
T. Rowe Price Associates first reported a position in DCPH in Q3 2019 and held it in 18 quarters. The position peaked at $105M in Q4 2019. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- T. Rowe Price Associates reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- T. Rowe Price Associates sold 15,355 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $242K.
- T. Rowe Price Associates first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
- T. Rowe Price Associates's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $105M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.